• 1
    Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addiction-like behavior in the rat. Science. 2004; 305(5686):10141017.
  • 2
    Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction (Review). Philos Trans R Soc Lond B Biol Sci. 2008; 363(1507):31253135.
  • 3
    Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2009; 35(1):217238.
  • 4
    Le Merrer J, Becker JAJ, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev. 2009; 89(4):13791412.
  • 5
    MacDonald AF, Billington CJ, Levine AS. Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat. Am J Physiol Regul Integr Comp Physiol. 2003; 285(5):R999R1004.
  • 6
    Lingford-Hughes A, Watson B, Kalk N, Reid A. Neuropharmacology of addiction and how it informs treatment. Br Med Bull. 2010; 96:93110.
  • 7
    Trigo JM, Martin-García E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 2010; 108(3):183194.
  • 8
    Ramchandani VA, Umhau J, Pavon FJ, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2011; 16(8):809817.
  • 9
    Ray LA, Bujarski S, Mackillop J, Courtney KE, Monti PM, Miotto K. Subjective response to alcohol among alcohol-dependent individuals: effects of the mu-opioid receptor (OPRM1) gene and alcoholism severity. Alcohol Clin Exp Res. 2012; 37 Suppl 1: E11624.
  • 10
    Miranda R, Ray L, Justus A, et al. Initial evidence of an association between OPRM1 and adolescent alcohol misuse. Alcohol Clin Exp Res. 2010; 34(1):112122.
  • 11
    Miranda R, Reynolds E, Ray L, et al. Preliminary evidence for a gene-environment interaction in predicting alcohol use disorders in adolescents. Alcohol Clin Exp Res. 2013; 37(2):325331.
  • 12
    Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 2005; 62(1):5764.
  • 13
    Williams TM, Davies SJC, Taylor LG, et al. Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol. 2009; 19(10):9.
  • 14
    Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012; 36(11):20002007.
  • 15
    Chamorro A-JA, Marcos MM, Mirón-Canelo J-AJ, Pastor II, González-Sarmiento RR, Laso F-JF. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012; 17(3):505512.
  • 16
    Schacht JP, Anton RF, Voronin KE, et al. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013; 38:414422.
  • 17
    Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006; 295(17):20032017.
  • 18
    Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology. 2004; 173(1–2):3240.
  • 19
    Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010; 8(12):CD001867.
  • 20
    Ignar DM, Goetz AS, Noble KN, et al. Regulation of ingestive behaviors in the rat by GSK1521498, a novel-opioid receptor-selective inverse agonist. J Pharmacol Exp Therap. 2011; 339(1):2434.
  • 21
    Rabiner EA, Beaver J, Makwana A, et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011; 16(8):826835.
  • 22
    Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everitt BJ. Attenuation of cocaine and heroin seeking by µ-opioid receptor antagonism. Psychopharmacology. 2013; 227(1):137147.
  • 23
    Nathan PJ, O'Neill BV, Bush MA, et al. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel µ-opioid receptor inverse agonist. J Clin Pharmacol. 2012; 52(4):464474.
  • 24
    Nathan PJ, Bush MA, Tao WX, et al. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the opioid receptor inverse agonist GSK1521498. J Clin Pharmacol. 2012; 52(10):14561467.
  • 25
    Ziauddeen H, Chamberlain SR, Nathan PJ, et al. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry. 2012; 17. doi: 10.1038/mp.2012.154
  • 26
    Cambridge VC, Ziauddeen H, Nathan PJ, et al. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biol Psychiatry. 2012; 73(9):887894.
  • 27
    Chamberlain SR, Mogg K, Bradley BP, et al. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals. Psychopharmacology. 2012; 224(4):501509.
  • 28
    Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974; 47(3):211218.
  • 29
    McNair DM, Heuchert JP. Profile of Mood States–Technical update, 2005. Multi-Health System: New York; 2005.
  • 30
    Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983; 67(6):361370.
  • 31
    Beck AT, Steer RA, Brown CK. Manual for Beck Depression Inventory-II San Antonio, TX: Psychological Corporation; 1996.
  • 32
    Steer RA, Rissmiller DJ, Ranieri WF, Beck AT. Structure of the computer-assisted Beck Anxiety Inventory with psychiatric inpatients. J Pers Assess. 1993; 60(3):532542.
  • 33
    Posner K, Oquendo M, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007; 164(7):10351043.
  • 34
    Shah J, Wesnes KA, Kovelesky RA, Henney HR. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Therap. 2006; 28(9):10.
  • 35
    Bohn MJM, Krahn DDD, Staehler BAB. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995; 19(3):600606.
  • 36
    Martin CSC, Earleywine MM, Musty RER, Perrine MWM, Swift RMR. Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res. 1993; 17(1):140146.
  • 37
    Field M, Mogg K, Zetteler J, Bradley BP. Attentional biases for alcohol cues in heavy and light social drinkers: the roles of initial orienting and maintained attention. Psychopharmacology. 2004; 176(1):8893.
  • 38
    Nathan PJ, O'Neill BV, Mogg K, et al. The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int. J. Neuropsychopharm. 2012; 15(2):149161.
  • 39
    McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000; 44(6):16861690.
  • 40
    Modi NB, Dresser M, Desai D, Edgar C, Wesnes K. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007; 47(3):315322.